News
The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...
8h
MyChesCo on MSNFDA Shuts Down Sarepta Gene Therapy Trials After Three Deaths Linked to Liver FailureThe U.S. Food and Drug Administration on Friday placed Sarepta Therapeutics’ gene therapy trials for limb girdle muscular ...
The third death occurred in an adult male with limb girdle muscular dystrophy who received a Sarepta AAVrh74 gene therapy product, SRP-9004, in a phase 4 clinical trial.
A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.
Separately, the FDA on Friday informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, that is approved to treat a different type of muscular dystrophy and was ...
FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...
23h
Stocktwits on MSNGlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s WhyRetail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF ...
The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...
Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...
Sarepta Therapeutics announced it is laying off nearly 500 employees this week, including 80 at its Easton location.
The FDA asked Sarepta Therapeutics to halt shipments of its Elevidys gene therapy after a patient's death linked to a similar treatment. Sarepta will continue shipments for ambulatory patients but ...
The FDA is set to request Sarepta Therapeutics to halt shipments of its gene therapy, Elevidys, after a third patient's death ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results